CDKN2A Polyclonal Antibody

Verified Samples in WB: HeLa, 293
Verified Samples in IHC: Human endometrium cancer, Human cervix cancer

WB 1:500-1:1000, IHC 1:400-1:800

Polyclonal

IgG

Recombinant Human CDKN2A protein expressed by E.coli

CDKN2A

CCM2, CDK4 inhibitor p16 INK4, Cell cycle negative regulator beta, Cyclin dependent kinase 4 inhibitor A, Cyclin Dependent Kinase Inhibitor 2A, Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4), Cyclin dependent kinase inhibitor 2A isoform 4, Cyclin dependent kinase inhibitor 2A isoforms 1/2/3, Cyclin dependent kinase inhibitor p16, Multiple tumor suppressor 1, INK, CMM, CDKN, P16INK, MTS, CDKN2A, ARF, CDK4I, CDKN2, CMM2, INK4, INK4A, MLM, MTS-1, MTS1, P14, P14ARF, P16, P16-INK4A, P16INK4, P16INK4A, P19, P19ARF, TP16, Cyclin-dependent kinase inhibitor 2A

14 kDa

16 kDa

Cytoplasm, Nucleus

Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific.

1 mg/mL

Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.

PBS with 0.05% proclin 300, 1% protective protein and 50% glycerol,pH7.4

Antigen Affinity Purification

Cell Biology, Epigenetics and Nuclear Signaling, Cancer

Unconjugated

Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.